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Dear Home Secretary, 
  
Re: ACMD advice on O-desmethyltramadol 
 
I am writing to provide you with the Advisory Council on the Misuse of Drugs‟ 
(ACMD) consideration of the compound O-desmethyltramadol.  
 
O-desmethyltramadol (2-((dimethylamino)methyl)-1-(3-
hydroxyphenyl)cyclohexanol) is the major metabolite of tramadol ((±)-trans-2-
((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol) and is a 
significantly more potent opiate than its parent drug.  
The compound came to light as a material of concern during the ACMD‟s 
review of tramadol. The ACMD has sufficient concerns about the harmful 
properties of O-desmethyltramadol to submit advice separately and in 
advance of that on tramadol (scheduled for December 2012) so that early 
Ministerial consideration of the metabolite can be made.    
O-desmethyltramadol is being offered for sale as a „legal high‟ and has been 
identified as an undeclared ingredient of a „legal high‟ product called „Krypton‟.  
„Krypton‟ is sold as an herbal material, claimed to consist of Kratom leaves 
(Mitragyna speciosa) from a Southeast Asian tree which, when chewed, 
produce narcotic and opiate-like effects. The packaging of „Krypton‟ is very 
similar to that of „Spice‟ (an herbal material containing synthetic 
cannabinoids), that is, brightly printed foil sachets containing a few grams of 
ground herbal material of unknown origin and authenticity. As with „Spice‟, the 
apparently natural herbal product has been found to be „spiked‟, in this case 
with synthetic O-desmethyltramadol, to produce additional psychoactive 
effects1. 
Toxicology reports from Germany have identified traces of O-
desmethyltramadol in the urine of „Krypton‟ users without evidence of use of 
tramadol or N-desmethyltramadol, another major tramadol metabolite. This 
indicates that the users had been exposed directly to O-desmethyltramadol2,3. 
In late December 2010, authorities in Sweden reported a series of 9 fatalities 
associated with use of „Krypton‟, apparently resulting from opiate-type 
respiratory depression, which could also result from Kratom ingestion. The 
presence of O-desmethyltramadol in urine samples in the absence of 
tramadol or other tramadol metabolites again indicated that the users had 
been exposed directly to O-desmethyltramadol. The authors suggested that 
the addition of the potent opiate synthetic O-desmethyltramadol to the 
naturally occurring opiate 7-hydroxymitragynine in herbal Kratom produced a 
lethal mixture4. 
   
Pharmacological studies indicate that O-desmethyltramadol is significantly 
more potent in activating µ-opiate receptors than its parent drug, and that it 
may account for most of tramadol‟s opiate-mediated activity. It is not in use as 
a pharmaceutical. As O-desmethyltramadol is a major, and pharmacologically 
active, metabolite of tramadol, the ACMD considers that the harms associated 
with the use of O-desmethyltramadol are similar to those of tramadol, for 
example confusion, dizziness, respiratory depression and seizures.  
The harms associated with the use of O-desmethyltramadol are 
commensurate with other substances controlled as Class B under the Misuse 
of Drugs Act 1971. The ACMD therefore recommends that O-
desmethyltramadol is controlled under the Misuse of Drugs Act 1971 as a 
Class B substance and, as it has no legitimate medical use, scheduled as a 
Schedule I substance under the Misuse of Drugs Regulations 2001.   
 
Yours sincerely  
 
Professor Les Iversen  
Cc: Parliamentary Under Secretary of State for Health 
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